Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594708 | 0.89 | KDM4E (0.33) | NCF1KDM4ETDP1 | |
| SCHEMBL3587614 | 0.88 | NCF1 (0.35) | NCF1HRH3KDM4EACHE | |
| SCHEMBL16675700 | 0.78 | KDM1A (0.33) | NCF1 | |
| SCHEMBL12027664 | 0.78 | KDM1A (0.33) | NCF1 | |
| SCHEMBL20322474 | 0.75 | HRH3 (0.33) | HRH3KDM4E | |
| SCHEMBL22570156 | 0.74 | MEN1 (0.45) | NCF1HRH3KDM4EACHE | |
| SCHEMBL7943522 | 0.74 | MEN1 (0.45) | NCF1HRH3KDM4EACHE | |
| SCHEMBL22570309 | 0.74 | MEN1 (0.45) | NCF1HRH3KDM4EACHE | |
| SCHEMBL81624 | 0.73 | L3MBTL1 (0.39) | NCF1HRH3KDM4ETDP1ACHE | |
| SCHEMBL22179237 | 0.72 | NCF1 (0.35) | NCF1HRH3KDM4EACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | NCF1 623/4885HRH3 3567/4885KDM4E 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.